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One Step Forward and Two Steps Back With
Drug-Eluting-Stents
From Preventing Restenosis to Causing Late Thrombosis
and Nouveau Atherosclerosis*
Gaku Nakazawa, MD,† Marc Vorpahl, MD,† Aloke V. Finn, MD,‡ Jagat Narula, MD, PHD,§
Renu Virmani, MD†
Gaithersburg, Maryland; Atlanta, Georgia; and Irvine, CaliforniaPercutaneous coronary intervention with intra-
coronary stenting is the most widely performed
procedure for the treatment of symptomatic coro-
nary disease (1). Although drug-eluting stents
(DES) have minimized the major limitation of
bare-metal stents (BMS), i.e., restenosis, stent
thrombosis has emerged as an important late com-
plication of this technology. The primary patho-
logic substrate underlying all cases of late stent
See page 616
thrombosis is the lack of complete endothelializa-
tion of stent struts. Angioscopy studies have dem-
onstrated that the incidence of uncovered struts in
patients receiving DES is substantially high: up to
20% at 2 years (2). However, the reported rate of
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Flow, and Atrium Medical Corporation.late stent thrombosis is not as high and it seems that
other mechanisms in addition to delayed healing
may be important in the pathophysiology of stent
thrombosis.
In this issue of the iJACC, Higo et al. (3) propose
development of nouveau atherosclerotic plaques
within the stented segment as another possible
substrate for late thrombosis after DES placement.
In their intracoronary angioscopy study in 57 pa-
tients, there was a 35% increase in the maximum
yellow color grade of the neointima within 10
months after sirolimus-eluting stent (SES) implan-
tation. Even among lesions that did not have yellow
plaque at baseline, yellow color was detected in 95%
of lesions. Of note, intramural thrombus was exclu-
sively associated with the yellow neointima in the
stented segments, and white neointima did not
show adherent surface thrombus.
The yellow color on gross pathological examina-
tion of the arterial wall indicates the presence of
lipid deposition such as fatty streaks and fibroathe-
roma (4). Fatty streaks consist of minimal intimal
thickening with accumulation of lipid-laden foamy
macrophages; such a lesion usually corresponds to
relatively less intense yellow color on angioscopic
examination. On the other hand, fibroatheroma,
especially with a large necrotic core and a thin
fibrous cap, imparts an intense yellow color on
angioscopy (5). The intense yellow appearance has
been commonly reported in patients presenting with
acute myocardial infarction (AMI) (6,7). It is conceiv-
able that the presence of an intense yellow hue in the
stented segments represents an advanced atheroscle-
rotic plaque, which may rupture with time.
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626The present study also demonstrated substan-
ially lower neointimal coverage of stent struts of
he SES segments as compared with BMS (3). The
elayed healing is consistent with results from
revious angioscopy reports (8,9), and autopsy stud-
es (10). Histopathologically, the drug-eluting-
tented segments are characterized by lack of
mooth muscle cell proliferation, persistent fibrin
eposition, and incomplete endothelialization (10).
he presence of “uncovered struts” is significantly
reater in DES with thrombosis as compared with
hose without, and the number of uncovered struts
s closely associated with an increased incidence of
ate stent thrombosis (11). Therefore, lack of strut
overage should lend itself to in vivo imaging
echniques for assessment of risk of future throm-
otic complications. In addition to angioscopic
tudies, optical coherence tomography (OCT) has
een used to identify uncovered struts or stent
alapposition (12–14). Unfortunately, it is difficult
o conduct large clinical trials using these invasive
maging modalities. Therefore, such studies have
een limited by small sample size and are more
hallenging for the detection of low incidence end
oints such as late stent thrombosis. Currently,
here are no prospective data available for in vivo
maging and its impact on clinical outcomes.
oes Angioscopic Yellow in Stented Segment
epresent Nouveau Atherosclerosis?
o find a pathological explanation of the observa-
ions of yellow neointima in SES segments pre-
6 9 12 18<3 24 48
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Graph Showing Percentage of Patients With Atherosclerotic
DES Versus BMS in Relation to Duration of Implant at Autopsy
therosclerotic change in sirolimus-eluting stents is seen in 40%
9 months; in bare-metal stent (BMS), the atherosclerotic change
egin to appear until 2 years and remains a rare ﬁnding until 4
 drug-eluting stent(s).ented by Higo et al. (3), we reviewed autopsy cases mrom the CVPath (Gaithersburg, Maryland) stent
egistry. Sixty-six SES segments from 52 cases were
ompared with 77 BMS lesions. In the stented
egments, restenosis was defined as 75% cross-
ectional area narrowing by neointimal formation,
nd an atherosclerotic change was defined as the
resence of lipid-laden foamy macrophage infil-
rates within the neointima above the stent (with or
ithout necrotic core formation) that did not com-
unicate with the underlying atherosclerotic
laque. Restenosis was significantly more frequent
n BMS (33 of 77; 43%) than DES (5 of 66; 8%,
 0.0001). However, the incidence of atheroscle-
otic change was seen in 10% of BMS lesions (8 of 77)
ompared with a significantly higher incidence in
ES lesions (35%; 23 of 66; p  0.0004). There was
significant difference in the timing of atherosclerotic
hange; earliest atherosclerotic change in DES, which
onsisted of foamy macrophage infiltration, was ob-
erved at 4 months after stent implantation. On the
ther hand, the atherosclerotic change occurred only
eyond 2 years in BMS and remained a rare finding
ntil 4 years (Figs. 1 and 2). The earliest necrotic core
ormation in DES was observed at 9 months com-
ared with 5 years in BMS. Of the 9 DES restenosis
ases, 2 lesions showed severe atherosclerotic change
onsisting of necrotic core formation with cholesterol
lefts and plaque hemorrhage.
Although the patient population in the study by
igo et al. (3) and our autopsy study are different,
e believe that yellow neointima by angioscopy
ost likely corresponds to either foamy macro-
hage infiltration and/or necrotic core formation;
he intensity of yellow likely signifies necrotic core
ith a thin fibrous cap as previously reported in
atients presenting with AMI.
hy is There Greater Incidence of
ngioscopic Yellow in DES?
ngioscopy studies have reported that the neointi-
al coverage in BMS, which mostly consists of a
hite neointima (3,15), typically occurs by 3
onths. This finding is consistent with the patho-
ogic studies wherein neointimal coverage of BMS
s almost completed by 3 to 6 months (16). The
eointima in BMS is made up of smooth muscle
ells and extracellular matrix (17), which typically
mparts a white hue on angioscopic examination.
onversely, a yellow neointima was more com-(%
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627n atherosclerotic change. The question arises as to
hy SES induces (or accelerates) the process of
therosclerosis. Normally, coronary artery vessel
alls are protected from lipid transport across the
essel wall by maintaining an efficient endothelial
arrier. Plaque progression is initiated by endothe-
ial dysfunction or damage that allows increased
ermeability of lipoproteins and upregulation of
dhesion molecules (18). As reported previously both
t autopsy and in animal models of DES, the endo-
helial lining is incompetent and therefore it is not
urprising that it will allow accelerated infiltration of
ipid as well as monocyte adherence and sub-
ndothelial migration. Sirolimus suppresses not only
mooth muscle cell but also endothelial cell regrowth
nd therefore may further enhance the formation of
therosclerotic change. It is possible that underlying
therosclerotic lesions progress even more rapidly after
ES implantation than do native coronary plaques
ith eventual luminal thrombosis (19).
The findings from the study by Higo et al. (3)
nd our pathological data presented here support
he concept that DES therapy may enhance athero-
clerosis while reducing restenosis. Indisputably, cor-
nary stents help to improve quality of life by relieving
nginal symptoms, but stent therapy remains only
alliative. The treatment of coronary artery disease
ould need a multidimensional approach, and the
ght against atherosclerosis is yet to be won. The
echnology of DES has certainly moved the field
orward but at a price—late stent thrombosis and now
ccelerated atherosclerosis and potentially greater late
hrombosis.
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no atherosclerotic change (F). DES  drug-eluting stent(s).E F E R E N C E S
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Figure 2. Representative Cases for Atherosclerotic Change After DES
Implantation
(A and B) Histologic sections from 58-year-old man with a sirolimus-eluting
stent (SES) implanted in the left circumﬂex coronary artery for 12 months.
Stented artery shows widely patent lumen (A) higher magniﬁcation image. (B)
Foamy macrophage inﬁltrates (arrowheads) with early necrotic core formation
(arrows). (C and D) Histologic sections from a 44-year-old man with SES
implantation in ramus intermedius branch 13 months antemortem, who died of
acute coronary thrombus secondary to the plaque rupture in the nonstented
artery. A low magniﬁcation image shows severely narrowed lumen (C); early
necrotic core formation with cholesterol clefts (arrows) is seen at higher magni-
ﬁcation image (D). (E and F) Representative bare-metal stent (BMS) images at
15 months. Histologic sections were obtained from a 49-year-old man with BMS
implantation in the left anterior descending 15 months antemortem, who died
suddenly because of diffuse coronary artery disease. A low magniﬁcation image
shows moderate narrowing of the lumen (E). The neointima consists of smooth
muscle cell in a proteoglycan and collagen matrix with mild inﬂammation butColl Cardiol 2001;38:1916–22.
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